Long-Term Prognosis for Clinical West Nile Virus Infection by Klee, Anne Labowitz et al.
Relatively little is known about the long-term prognosis
for patients with clinical West Nile virus (WNV) infection.
We conducted a study to describe the recovery of New
York City residents infected during the 1999 WNV
encephalitis outbreak. Patients were interviewed by tele-
phone on self-perceived health outcomes 6, 12, and 18
months after WNV illness onset. At 12 months, the preva-
lence of physical, functional, and cognitive symptoms was
significantly higher than that at baseline, including muscle
weakness, loss of concentration, confusion, and  lighthead-
edness. Only 37% achieved a full recovery by 1 year.
Younger age at infection was the only significant predictor
of recovery. Efforts aimed at preventing WNV infection
should focus on elderly populations who are at increased
risk for neurologic manifestations and more likely to experi-
ence long-term sequelae of WNV illness. More studies are
needed to document the long-term sequelae of this
increasingly common infection.
W
est Nile virus (WNV, family Flaviviridae, genus
Flavivirus) has become endemic throughout much
of the United States since its introduction in 1999 (1). In
2003, a total of 2,866 laboratory-confirmed human cases
of neuroinvasive illness and 264 deaths were caused by
WNV infection (2). Older persons are at substantially
increased risk for severe WNV disease, a hallmark of
which is profound muscle weakness (1), often with acute
flaccid paralysis or other motor disorder (2–4).
Investigators of the first WNV disease outbreak in
North America in 1999 documented that older persons and
persons with diabetes are at increased risk for death after
WNV infection (1,5–7) However, few epidemiologic stud-
ies have examined the sequelae or time course of recovery
from WNV meningitis or encephalitis in survivors. A
recent investigation of neurologic manifestations of WNV
infections showed persistent symptoms at 8 months after
infection, particularly in those patients who experienced
flaccid paralysis (8).
We conducted an 18-month follow-up study on a cohort
of New York City (NYC) case-patients identified as being
ill with WNV infection in 1999 (1). The investigation had
the following objectives: 1) to describe the physical, cogni-
tive, and functional outcomes in patients recovering from
WNV meningitis or encephalitis over the 18 months after
acute illness and 2) to determine whether the severity of the
initial clinical syndrome, the patient’s age, and the patient’s
underlying illness affected the likelihood of recovery. 
Methods
The medical records of all patients hospitalized with
WNV infections were reviewed by using a standard form
to abstract chart information. Follow-up interviews were
conducted and blood was collected at approximately 6-
month intervals from laboratory confirmed case-patients
whose WNVinfections were diagnosed in 1999. Three dis-
tinct health outcome areas—physical, cognitive, and func-
tional health status—were each assessed at 6, 12, and 18
months after illness onset. Baseline health status was
assessed by recall at the 12-month interview. Physical and
cognitive health status outcomes were assessed at each
interview by asking about the frequency of selected symp-
toms (Table 1). Functional ability was evaluated by admin-
istering the Instrumental Activities of Daily Living Scale
(IADLS) (9) to assess daily functioning before and after
WNV illness. The prevalence of physical, cognitive, and
functional symptoms at baseline (by recall at 12 months)
and at the 6-, 12-, and 18-month interviews was calculat-
ed. Underlying illness and initial clinical syndrome were
ascertained from the medical chart. 
The initial clinical syndrome was classified as WNV
encephalitis, indicated by fever and altered mental status
or other cortical signs (e.g., seizures) and cerebrospinal
fluid (CSF) suggestive of viral infection; WNV meningitis,
indicated by fever, meningeal signs (documentation of
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suggestive of viral infection; or WNVfever with headache.
CSF suggestive of viral infection was defined as a negative
bacterial stain and culture, with elevated leukocyte count
(>5 cells/mm3) or elevated protein (>4.5 g/L). Proxy inter-
views were conducted when case-patients could not be
interviewed because of poor health, hearing difficulties, or
a language barrier.
Laboratory Methods
Laboratory evidence for recent WNV infection (10)
was confirmed in all patients and defined by any of the fol-
lowing test results: 1) isolation of WNV by culture or
amplification of WNVRNAby reverse transcriptase–poly-
merase chain reaction testing from human tissue speci-
mens; 2) demonstration of immunoglobulin (Ig) M
antibody to WNV in CSF by IgM-capture enzyme-linked
immunosorbent assay (ELISA); 3) greater than fourfold
serial change in WNV-specific neutralizing antibody as
measured by the plaque-reduction neutralization test
(PRNT) in paired, appropriately timed serum samples; or
4) demonstration of both WNV-specific IgM (by ELISA)
and IgG (screened by ELISA and confirmed by PRNT) in
a single serum specimen. Patients with WNV-specific IgM
in a single serum sample were classified as having a prob-
able recent infection. Patients with anti-WNV IgG only in
a single serum specimen were also classified as having a
probable WNV infection if the antibodies were found to be
WNV-specific by PRNT and the patient had no history of
travel to an area outside the United States where WNV
infection is endemic.
Blood specimens were obtained at 6-month intervals
starting at 6 months through 18 months after illness onset,
until WNV-specific IgM, indicative of recent infection, was
undetectable. Serum samples were tested for anti-WNV
IgM (capture ELISA) and IgG (indirect ELISA) (11,12).
Results from the ELISA testing were expressed as a WNV-
positive to WNV-negative control (P/N) ratio of observed
A450 nm (MAC-ELISA) or A405 nm (IgG ELISA) as
described. In these tests, P/N ratios >3.0 were considered
positive and P/N ratios >2.0 and <3.0 were considered
equivocal. Detailed information on WNVserologic features
in this cohort study has been previously published (13).
Study Population
Of the 59 surviving patients hospitalized with WNV
infection in 1999, 40 were NYC residents and eligible for
inclusion in the follow-up study. During the course of the
study, two additional patients with laboratory-confirmed
WNV infection who had fever and headache were identi-
fied and enrolled. Thirty-eight (90.5%) of the 42 case-
patients completed the first interview (6 months
postonset), 35 (83.3%) participated in the second interview
(12 months postonset), and 36 (85.7%) participated in the
third interview (18 months postonset). Forty (95%) case-
patients participated in at least one of the three interviews;
32 (76%) completed all three interviews. The proportion of
interviews that were completed by proxy was 39% at the
first interview to 25% at the third interview. 
Recovery Assessment at 12 Months After Infection
A recovery assessment was completed for the 35 case-
patients who participated in the 12-month interview. At the
12-month interview, patients responded to questions on the
frequency of occurrence (never, sometimes, or often) of
selected symptoms during the month before the interview
and during the month before illness onset (baseline). A
symptom was counted as being present if it was experi-
enced sometimes or often. Current and baseline composite
scores were calculated within each health status domain by
tabulating the responses for each outcome in that domain.
Difficulty walking was weighted double in computing the
physical health domain score, because it appears to be a
very specific symptom of severe WNV infection (1,3,4). If
a response of not applicable or unknown was given for a
particular outcome, then that outcome was not included in
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Table 1. Health outcomes assessed during follow-up telephone interviews of New York  residents with clinical West Nile virus infection 
in 1999
a,b 
Physical health   Cognitive health   Functional health  
Difficulty walking
c 
Fatigue 
Headache 
Insomnia 
Joint pain 
Muscle pain 
Muscle weakness  
Seizures 
Stiff neck 
Confusion 
Depression 
Irritability 
Lightheadedness  
Loss of concentration  
Loss of memory  
Heavy chores 
Laundry 
Light housekeeping  
Managing medications  
Managing money  
Meal preparation  
Shopping 
Telephoning 
Transportation 
aAt 12 months post -onset, baseline status for each outcome was assessed; for each outcome, patients were asked to report the degree to which they 
experienced the signs and symptoms at baseline (by recall) and at 12 months postonset.  
bEach outcome w as scored 0–2 according to the following scale: always = 2, sometimes = 1, never = 0. Functional health was scored according to how 
frequently the patient had difficulty performing the task. Recovery was calculated as the sum of the baseline score in each category, divided by the sum of 
the 12-month score. 
cDifficulty walking was given twice the weight as other outcomes in the recovery score calculation.  calculating that case-patient’s baseline or 12-month com-
posite score. 
Within each health status domain, the ratio of the 12-
month composite score to the baseline composite score
was calculated and used as a measure of recovery for that
domain. Persons with a 12-month composite score >85%
of baseline for a given health status domain were consid-
ered to be recovered in that domain. Those persons with
12-month composite >85% of baseline in all three health
status domains were considered fully recovered.
Statistical Methods
Prevalence ratios were calculated for all outcomes at
each interval relative to baseline; p values associated with
prevalence ratios were calculated by using a matched
analysis with McNemar test for correlated proportions.
Crude and adjusted relative risks (RRs) were calculated to
examine the relationships of clinical syndrome (i.e.,
encephalitis, meningitis, and mild illness), age, and under-
lying medical conditions with recovery in each health sta-
tus domain at 12 months postonset. RRs were adjusted by
using the method of Mantel and Haenszel. Data were ana-
lyzed by using the SPSS System for Windows, version
10.0 and SAS Version 8 (SAS Institute, Cary, NC). 
Consent and Human Subjects Review
Verbal consent was obtained from participants during
telephone interviews, and written consent was obtained
before each follow-up blood specimen collection. The
study protocol underwent human subjects review and was
approved by institutional review boards of both the New
York City Department of Health and Centers for Disease
Control and Prevention.
Results
Table 2 shows the patients who were ill with WNV
infection in 1999 (N = 59) and the 40 surviving NYC resi-
dents who were eligible for participation in the follow-up
study, plus 2 additional patients with West Nile virus dis-
ease who were not hospitalized. Of the 40 surviving NYC
case-patients participating in one or more interviews, the
median age of the participants at illness onset was 68 years
(range: 16 to 90 years), and all patients resided in their own
homes before illness. At the time of diagnosis, 22 (55%)
patients had encephalitis, 11 (27.5%) had meningitis, and 7
(17.5%) had illness characterized by fever and headache.
Of 33 hospitalized patients with known disposition at dis-
charge, those who had diagnoses of encephalitis were more
likely to have discharge placements outside their homes (p
< 0.05) and more likely to be >65 years of age (p < 0.001).
Physical, Cognitive, and Functional Health Status
Table 3 shows the prevalence of physical, cognitive,
and functional sequelae reported at 6, 12, and 18 months
postonset. At the 12-month interview, patients were also
asked to recall the prevalence of those symptoms before
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Table 2. Characteristics of participating and nonparticipating patients who survived clinical West Nile virus infection, New York City, 1999  
Characteristic  
All hospitalized  
 patients, N = 59 (%)  
Enrolled patients,   
N = 42 (%) 
Participants in 12-month 
interview, N = 35 (%)  
Nonparticipants in 12-month 
interview, N = 7 (%)  
Age         
<65  23 (39)  16 (38)  13 (37)  3 (43) 
≥65  36 (61)  26 (62)  22 (63)  4 (57) 
Sex         
Female  28 (47)  20 (48)  18 (51)  2 (29) 
Male  31 (53)  22 (52)  17 (49)  5 (71) 
Underlying illness before 
infection 
       
Hypertension  25 (42)  17 (40)  14 (40)  3 (43) 
Diabetes  12 (20)  6 (14)  5 (14)  1 (14) 
Hypertension or diabetes   31 (53)  19 (45)  16 (46)  3 (43) 
Clinical syndrome          
Encephalitis  37 (63)  22 (52)  19 (54)  3 (43) 
Meningitis or milder illness   22 (37)  20 (48)  16 (46)  4 (57) 
Discharge status
a         
Dead  7 (12)  NA  NA  NA 
Home  22 (37)  20 (50)
b  20 (61)
c  NA 
Home of family or friend   3 (5)  3 (8)
b  3 (9)
c  NA 
Skilled nursing facility   4 (7)  4 (10)
b  4 (12)
c  NA 
Rehabilitation  6 (10)  6 (15)
b  6 (18)
c  NA 
Unknown but alive   17 (29)  7 (18)
b  0  7 (100) 
Required physical therapy   NA  NA  18 (51)  NA 
aIncludes hospitalized patients only.  
bN = 40 for these calculations.  
cN = 33 for these calculations.  illness onset. All participants interviewed with a clinical
diagnosis of encephalitis with weakness (n = 10) reported
difficulty walking 6 months after illness. Those who had
an initial diagnosis of encephalitis were more likely to
require a wheelchair at the first follow-up interview than
those with meningitis or mild illness.
The prevalence of cognitive symptoms was higher 1
year after illness compared with baseline for all cognitive
outcomes. All cognitive symptoms were more common
after illness onset in case-patients at intervals extending up
to 18 months after acute illness (Table 3), and some symp-
toms did not diminish over time. Prevalence ratios of
functional disabilities were also significantly elevated
compared with baseline.
Analysis of Recovery Outcomes
The mean domain-specific health status score was sig-
nificantly lower at 12 months compared with baseline for
all three domains (data not shown). Overall, 54%, 59%,
and 57% of patients were physically, cognitively, or func-
tionally recovered, respectively (Table 4). Case-patients
>65 years achieved recovery rates of 50%, 52%, and 45%
in the respective domains of physical recovery, cognitive
recovery, and functional recovery (Table 5). Only 37% of
patients were considered fully recovered. Diagnosis
(encephalitis versus meningitis or other mild illness) was
not predictive of physical or cognitive recovery (Table 4),
even after adjusting for age. Age was a positive predictor
of recovery in each domain, with younger persons more
likely to achieve physical, cognitive, and functional recov-
ery (Table 5). The absence of an underlying health condi-
tion was associated with an increased likelihood of
recovery in all domains (Table 6). After adjusting for base-
line clinical status (Mantel-Haenszel method), younger
persons (<65 years) were significantly more likely to
achieve a full recovery than older persons (>65 years) (rel-
ative risk [RR] = 3.3, 95% confidence interval [CI]
1.1–9.9). After adjusting for underlying illness, younger
persons were also more likely to recover fully than older
persons (RR = 2.3, 95% CI 0.97–5.5).
Discussion
We report that WNV infection can result in a protract-
ed convalescent period with long-term physical, cognitive,
and functional impairments lasting >18 months after acute
illness. Approximately 40% of patients hospitalized in
1999 did not return to their own homes immediately after
discharge, and physical therapy was required by 47% of
patients after hospitalization. Comparing the prevalence of
symptoms before illness with that at 12 months after WNV
illness onset, physical, functional, and cognitive symptoms
persisted. We estimate that 37% achieved full recovery by
12 months. Younger age (<65 years) was the only signifi-
cant predictor of achieving a full recovery. 
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Table 3. Prevalence of signs and symptoms at intervals of follow-up in patients with clinical West Nile virus infection, New York City, 
1999 
Sign or symptom  
Before illness onset
a 
(baseline), n/N (%)  
Interview 1  
(6 months), n/N (%)  
Interview 2  
(12 months), n/N (%) 
Interview 3  
(18 months), n/N (%)  
p value for 12 
months vs. 
baseline
b 
Physical sequelae            
Difficulty walking   7/35 (20.0)  30/38 (78.9)  17/35 (48.6)  15/36 (41.6)  0.002 
Muscle weakness   4/35 (11.5)  25/38 (65.8)  15/34 (44.1)  20/36 (55.5)  < 0.001 
Fatigue  12/35 (34.3)  20/37 (54.1)  22/33 (66.7)  23/36 (63.8)  0.002 
Insomnia  7/35 (20.0)  17/38 (44.7)  16/34 (47.1)  17/36 (47.2)  0.007 
Muscle pain  12/35 (34.3)  14/37 (37.8)  19/34 (55.9)  14/36 (38.8)  0.035 
Headache  9/35 (25.7)  13/37 (35.1)  15/34 (44.1)  13/36 (36.1)  0.014 
Joint pain  7/35 (20.0)  12/38 (31.6)  11/34 (32.3)  11/36 (30.6)  0.157 
Cognitive symptoms            
Memory loss  7/35 (20.0)  21/38 (55.3)  17/34 (50.0)  16/36 (44.5)  0.002 
Loss of concentration  3/35 (8.6)  16/37 (42.2)  14/34 (41.2)  12/36 (33.3)  < 0.001 
Depressed  5/35 (14.3)  15/38 (39.5)  13/34 (38.2)  16/36 (44.4)  0.005 
Irritable  8/35 (22.9)  14/38 (36.8)  14/34 (41.2)  14/36 (38.9)  0.008 
Lightheaded  4/35 (11.5)  13/38 (34.2)  17/33 (51.5)  13/35 (37.1)  < 0.001 
Confusion  2/35 (5.7)  17/38 (44.8)  9/34 (26.5)  11/36 (30.6)  0.008 
Functional sequelae            
Shopping  4/33 (12.1)  17/36 (47.2)  14/33 (42.4)  14/35 (40.0)  0.002 
Meal preparation   2/32 (6.3)  22/31 (71.0)  12/32 (37.5)  12/34 (35.3)  < 0.001 
Laundry  1/25 (4.0)  14/29 (48.3)  10/25 (40.0)  10/33 (30.3)  0.003 
Light housekeeping   1/28 (3.6)  19/35 (54.3)  12/28 (42.9)  12/35 (34.3)  < 0.001 
Heavy chores  5/30 (11.9)  19/33 (57.6)  19/30 (63.3)  19/34 (55.9)  0.003 
Transportation  3/29 (10.3)  23/37 (62.2)  10/28 (35.7)  14/36 (38.9)  0.008 
aAssessed by recall at the 12-month follow-up interview.  
bBased on McNemar’s test for agreement in a matched analysis.  WNV is clinically, serologically, and epidemiological-
ly similar to St. Louis encephalitis virus (SLEV) (14–18),
and recovery after WNV infection might be comparable to
that of patients recovering from SLEV-associated
encephalitis (SLE). Information on sequelae from SLE
has been documented after U.S. outbreaks occurring from
the 1930s to the 1970s. Various methods assessed recov-
ery from SLE, including medical examinations (with neu-
rologic assessments) and patient or proxy interviews (19).
Follow-up times varied from 6 months to 5 years after
acute illness (15–23). In general, studies of recovering
patients with SLE have documented generalized suscepti-
bility to fatigue, headaches, nervousness, inability to con-
centrate, depression, and problems with gait and balance
throughout convalescent periods of 6 months to 3 years
after acute SLEV infection; on average, ≈30% of case-
patients were not fully recovered 1 year after acute illness
(19,20,24).
Different approaches to defining recovery were used by
researchers who characterized the experience of patients
after SLEV infection. After the first SLE epidemic in St.
Louis in 1933, researchers defined overall recovery based
on the ability to return to work. Of 331 patients, 141 (66%)
reported that they felt completely recovered 12–18 months
after acute illness, whereas 22 (6.7%) felt they were phys-
ically unable to return to their jobs. Although none of the
patients  <20 years of age was incapacitated, >10% of
patients >20 years could not return to work (20). After an
SLE epidemic in Mississippi in 1975, researchers conduct-
ed follow-up interviews 6 months after illness onset. Of
the 175 patients contacted, 87 (49.7 %) achieved full
recovery, 24 (13.7%) reported minor symptoms, and 29
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Table 4. Recovery at 12 months post-onset by health status domain and clinical syndrome at diagnosis in patients with clinical West 
Nile virus infection, New York City, 1999  
Recovery  Total  Recovered, n (%)
a  Not recovered, n (%)
a  Risk ratio  95% confidence interval 
Physical recovery            
Meningitis or mild illness   16  8 (50.0)  8 (50.0)  0.86  0.46–1.6 
Encephalitis  19  11 (57.9)  8 (42.1)  Referent   
Total  35  19 (54.3)  16 (45.7)     
Cognitive recovery            
Meningitis or mild illness   16  10 (62.5)  6 (37.5)  1.1  0.64–2.0 
Encephalitis  18  10 (55.5)  8 (44.4)  Referent   
Total  34  20 (58.8)  14 (41.2)     
Functional recovery            
Meningitis or mild illness   16  10 (62.6)  6 (37.5)  1.2  0.67–2.1 
Encephalitis  19  10 (52.6)  9 (47.4)  Referent   
Total  35  20 (57.1)  15 (42.9)     
Total recovery           
Meningitis or mild illness   16  7 (43.8)  9 (56.3)  1.4  0.58–3.3 
Encephalitis  19  6 (31.6)  13 (68.4)  Referent   
Total  35  13 (37.1)  22 (62.9)     
aDue to rounding, not all values add up to 100%.  
Table 5. Recovery at 12 months post-onset by health status domain and age at illness onset in patients with clinical West Nile virus 
infection, New York City, 1999  
Recovery  Total  Recovered, n (%)
a  Not recovered, n (%)
a  Risk ratio  95% confidence interval  
Physical recovery            
<65  13  8 (61.5)  5 (38.5)  1.2  0.68–2.2 
≥65  22  11 (50.0)  11 (50.0)  Referent   
Total  35  19 (54.3)  16 (45.7)     
Cognitive recovery            
<65  13  9 (69.2)  4 (30.8)  1.3  0.77–2.3 
≥65  21  11 (52.4)  10 (47.6)  Referent   
Total  34  20 (58.8)  14 (41.2)     
Functional recovery           
<65  13  10 (76.9)  3 (23.1)  1.7  0.98–2.9 
≥65  22  10 (45.5)  12 (54.5)  Referent   
Total  35  20 (57.1)  15 (42.9)     
Total recovery           
<65  13  8 (61.5)  5 (38.5)  2.7  1.1–6.5 
≥65  22  5 (22.7)  17 (77.3)  Referent   
Total  35  13 (37.1)  22 (62.9)     
aDue to rounding, not all values add up to 100%.  (16.6 %) reported that they resumed previous activities but
not at the same level. SLE patients from the Tampa Bay,
Florida, outbreaks occurring from 1959 to 1962 (N = 160)
had more difficulty completing tests that evaluated balance
and equilibrium than controls. In particular, SLE patients
had difficulty walking in straight lines and widening their
lateral base of support (25). Predominant cognitive prob-
lems included nervousness, irritability, depression, and
forgetfulness (15–23).
Our findings are similar to those reported in these SLE
studies. Regardless of acute clinical symptoms, WNVcase-
patients in this study continued to report difficulty walking,
muscle weakness, fatigue, and insomnia, with >40% report-
ing a combination of these difficulties, and 30% continued
to report persistence of memory loss, confusion, depres-
sion, and irritability at 18 months after acute illness.
Eighteen months after illness, 30% of case-patients report-
ed needing assistance with activities of daily living, mostly
those requiring increased strength. Although average func-
tional ability from 6 months to 1 year post-onset improved
significantly, functional ability reached a plateau and did
not improve further during the 12- to 18-month period. 
Our results suggest that WNV has more severe long-
term sequelae in older persons than in younger persons.
These sequelae may be attributable to the severity of the
patients’ WNV infection, to the more general effects of
serious illness and hospitalization, or to the aging process
itself; regardless, WNV causes severe neurologic illness
and might be associated with lasting sequelae in persons
>65 years.
The presence of underlying disease at the time of onset
of illness was not significantly associated with recovery at
12 months (RR = 1.4, 95% CI 0.58–3.3), even after adjust-
ing for age (adjusted RR = 1.3, 95% CI 0.70–2.5).
However, the lack of significance of this association could
be a result of the small number of patients in our study or
misclassification.
Several aspects of our investigation might limit the gen-
eralizability of these findings. Although participation was
high, our estimates may be imprecise because of the small
sample size. Furthermore, the ages of the study partici-
pants span a wide range (16–90 years), making adequate
adjusting for age difficult. We used a structured interview
questionnaire, the content and format of which, when pos-
sible, was similar across interviews to maximize compara-
bility of data obtained over time. Proxies were used when
case-patients could not be interviewed because of poor
health, hearing difficulties, or a language barrier. Data
were based on subjective report, either by the patient or
their proxy. Subjective accounts provided by persons who
are cognitively impaired might overattribute or underat-
tribute certain dysfunctions to their WNV illness, and
recall bias might have caused case-patients to selectively
suppress or exaggerate information about their health sta-
tus, either current or past. 
Baseline information regarding physical, cognitive, and
functional health before WNV disease was collected dur-
ing the second follow-up interview at 1 year (i.e., by
recall). Participants may have had problems recalling base-
line health status over a 12-month period, limiting our abil-
ity to accurately ascertain actual baseline level of
functioning. Sequelae could not be verified by objective
physical examination, physician interview, or medical
record review. Future studies of recovery in WNV patients
should attempt to obtain more objective measurements of
sequelae, such as provider interviews, medical chart
review, or  neurologic examination. As WNV continues to
affect older age groups, further research should consider
ways to control for declines in functioning associated with
the aging process and to obtaining objective data regarding
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Table 6. Recovery at 12 months postonset by health status domain and underlying health condition in patients with clinical West Nile 
virus infection, New York City, 1999  
Recovery  Total  Recovered, n (%)
a  Not recovered, n (%)
a  Risk ratio  95% confidence inte rval 
Physical recovery            
No underlying condition   18  11 (61.1)  7 (38.9)  1.3  0.70–2.4 
Hypertension or diabetes   17  8 (47.1)  9 (52.9)  Referent   
Total  35  19 (54.3)  16 (45.7)     
Cognitive recovery            
No underlying condition   17  11 (64.7)  6 (35.3)  1.2  0.70–2.2 
Hypertension or diabetes   17  9 (52.9)  8 (47.1)  Referent   
Total  34  20 (58.8)  14 (41.2)     
Functional recovery            
No underlying condition   18  12 (66.7)  6 (33.3)  1.4  0.78–2.6 
Hypertension or diabetes   17  8 (47.1)  9 (52.9)  Referent   
Total  35  20 (57.1)  15 (42.9)     
Total recovery           
No underlying condition   18  9 (50.0)  9 (50.0)  2.1  0.80–5.6 
Hypertension or diabetes   17  4 (23.5)  13 (76.5)  Referent   
Total  35  13 (37.1)  22 (62.9)     
aDue to rounding, not all values add up to 100%  baseline status. Finally, future studies should try to assess
the baseline health status of WNV patients closer to the
time of onset to reduce the impact of recall bias on long-
term measures of recovery.
Our study documents that, in addition to causing severe
acute illness, WNV meningitis ore ncephalitis results in a
prolonged recuperation and rehabilitation period, especial-
ly in older persons. As WNV continues to establish itself
as a national public health concern, these findings rein-
force the need for local governments in affected areas to
institute widespread public health measures to safeguard
against WNV transmission and for persons—especially
those age 65 and over —to take precautions to avoid expo-
sure to mosquitoes and reduce mosquito breeding sites on
their properties. More studies are needed to document the
long-term sequelae of this increasingly common infection.
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